Sort
16,300 grants matching “fatty liver disease”
CTRP9, a novel adipose tissue-secreted glycoprotein
$427,908Guang William Wong · Johns Hopkins University · R01 · FY2014 · DK
Long term efficacy and safety of orlistat for type 1 hyperlipoproteinemia: a randomized, double-blind, placebo-controlled trial
$427,779Abhimanyu Garg · Ut Southwestern Medical Center · R33 · FY2024 · HL
A Precision Targeted Therapeutics for Nonalcoholic Fatty Liver Disease
$427,741Wanqing Liu · Wayne State University · R01 · FY2022 · DK
Metabolic Engineering for Improved Liver Function
$427,702Massachusetts General Hospital · R01 · FY2005 · DK
Metabolic Engineering for Improved Liver Function
$427,702Massachusetts General Hospital · R01 · FY2004 · DK
Metabolic Engineering for Improved Liver Function
$427,702Massachusetts General Hospital · R01 · FY2003 · DK
Nutrition to Optimize, Understand, and Restore Insulin Sensitivity in HIV for Oklahoma (NOURISH OK)
$427,672Marianna Wetherill · University Of Oklahoma Hlth Sciences Ctr · R01 · FY2022 · DK
Hepatic mTORC1 Signaling and the Regulation of Lipid Homeostasis
$427,654Paul Michael Titchenell · University Of Pennsylvania · R01 · FY2023 · DK
Apolipoprotein conformation in amyloid and cardiovascular diseases
$427,652Olga Gursky · Boston University Medical Campus · R01 · FY2019 · GM
Apolipoprotein conformation in amyloid and cardiovascular diseases
$427,652Olga Gursky · Boston University Medical Campus · R01 · FY2020 · GM
Molecular Control of Muscle Fuel Metabolism
$427,627Daniel Patrick Kelly · University Of Pennsylvania · R01 · FY2019 · DK
Dietary sugar-regulated recombinant protein production in the gut
$427,625Jan-Peter Van Pijkeren · University Of Wisconsin-Madison · R21 · FY2025 · AI
Elucidating and targeting beta-cell senescence and its SASP
$427,500Cristina Aguayo-Mazzucato · Joslin Diabetes Center · R01 · FY2025 · DK
Microbiome as Therapeutic Target in Alcoholic Hepatitis
$427,499Bernd G. Schnabl · University Of California, San Diego · U01 · FY2017 · AA
Microbiome as Therapeutic Target in Alcoholic Hepatitis
$427,498Bernd G. Schnabl · University Of California, San Diego · U01 · FY2016 · AA
Periodontal Disease and Coronary Artery Remodeling in CHD and Metabolic Syndrome
$427,345Francine K Welty · Beth Israel Deaconess Medical Center · R01 · FY2010 · DE
Combining experiments of man and nature to target human insulin resistance
$427,297Amit Majithia · University Of California, San Diego · R01 · FY2022 · DK
Mapping diabetes susceptibility by expression traits in African Americans
$427,257Swapan Kumar Das · Wake Forest University Health Sciences · R01 · FY2012 · DK
Elucidating and targeting beta-cell senescence and its SASP
$426,979Cristina Aguayo-Mazzucato · Joslin Diabetes Center · R01 · FY2023 · DK
The Saint Louis University Component of the NASH Clinical Research Network
$426,708Brent A Neuschwander-Tetri · Saint Louis University · U01 · FY2017 · DK
Role of ATG14 in the regulation of hepatic function
$426,682Xiaocheng Charlie Dong · Indiana University Indianapolis · R01 · FY2020 · DK
OBESITY AND NONALCOHOLIC FATTY LIVER DISEASE
$426,654Samuel Klein · Washington University · R01 · FY2006 · DK
Clock modulation in circadian desynchrony induced diabetes and atherovascular disease - mechanisms and interventions
$426,625Vijay K Yechoor · University Of Pittsburgh At Pittsburgh · R01 · FY2022 · DK
Microbiota and Inflammation in Adiposity: The Ground Squirrel Model
$426,608Courtney C Kurtz · University Of Wisconsin Oshkosh · R15 · FY2022 · GM
MODULATING PHYSIOLOGIC EFFECTS OF PHOSPHOLIPID METABOLISM IN OBESITY AND DIABETES
$426,555Clay F. Semenkovich · Washington University · R01 · FY2016 · DK